Novo Nordisk to end semaglutide kidney study early due to strong efficacy signalsNovo Nordisk is ending its Phase III FLOW trial ahead of schedule after an interim analysis of the kidney outcomes study of semaglutide...
Tirzepatide found to reduce body weight regardless of duration of condition and BMI before treatment2 days ago